ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3005

Pulmonary Arterial Hypertension-Associated Single Nucleotide Polymorphisms of Hypoxia-Inducible Factor-3a Gene Cause Constitutive Activation of the Endothelin-1 Gene Promoter

Katsutoshi Mizumoto1, Kyohei Takatori1, Sayaka Takatori1, Ryota Yoshimoto1, Kohei Eguchi1, Daisuke Fujishiro1, Satoru Kodama1, Atsushi Kobayashi1, Kensaku Okamoto1, Yasushi Kawaguchi2, Masakazu Haneda1 and Yuichi Makino1, 1Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan, 2Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Gene Expression, polymorphism and pulmonary complications

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Pulmonary arterial hypertension (PAH) is a progressive and fatal complication in the patients with connective tissue diseases (CTD). Elevation of endothelin-1 (ET-1) levels in pulmonary arteries is suggested as one of the pathogenesis of PAH, however, mechanism for ET-1 induction in the disease circumstances is still elusive. A driving force for ET-1 synthesis is hypoxia and ET-1 has been known as a target gene of hypoxia-inducible factors (HIFs). HIFs are heterodimeric transcription factors composed of α subunit (HIF-1α or HIF-2α or HIF-3α) and β subunit (HIF-1β), operating in gene regulation in adaptive response to hypoxic condition. We have demonstrated ablation of HIF-3α gene in mice resulted in an increase in ET-1 production by pulmonary endothelial cells and human PAH-like cardio-pulmonary phenotype such as right ventricular enlargement and pulmonary arteriole musculalizations, indicating an implication of HIF-3α in the pathogenesis of PAH. In the present study, we aimed to explore the role of genetic defect or anomalies of HIF-3α in the pathogenesis of CTD-PAH.

Methods: Using genomic DNA form patients with systemic sclerosis (SSc) without PAH, SSc complicated with PAH, and normal healthy controls, we analyzed the incidence of coding single nucleotide polymorphisms (SNPs) in HIF3A gene reported in NCBI dbSNP database by PCR-direct sequencing. The m×n χ2–test was applied to examine statistical significance of the incidence of the SNPs. Functional validations of the HIF-3α carrying the SNPs (SNP-HIF3α) were performed in the cells overexpressing SNP-HIF3α. Effect of SNP-HIF3α on ET-1 gene promoter was analyzed by reporter gene assays and chromatin immunoprecipitation assays.

Results: We found coding SNPs in HIF3A gene with significantly higher incidence in the SSc patients complicated with PAH compared to the SSc patients without PAH. Overexpression of HIF-3α carrying the SNPs (SNP-HIF3α) in the cells resulted in induction of ET-1 mRNA even under normoxic condition, indicating an implication of SNP-HIF3α in dysregulation of ET-1 production. SNP-HIF3α showed higher affinity to HIF-1β and to ET-1 gene promoter irrespectively of oxygen concentrations compared to wild type HIF-3α. Interestingly, SNP-HIF3α seemed to employ an additional cis-acting DNA sequence proximity to hypoxia response element in ET-1 gene promoter for transcriptional activation of the gene.

Conclusion: PAH-associated coding SNPs confer a novel function on HIF-3α at ET-1 gene promoter, which might contribute to the derangement of ET-1 gene regulation in patients with CTD-PAH.   


Disclosure: K. Mizumoto, None; K. Takatori, None; S. Takatori, None; R. Yoshimoto, None; K. Eguchi, None; D. Fujishiro, None; S. Kodama, None; A. Kobayashi, None; K. Okamoto, None; Y. Kawaguchi, None; M. Haneda, None; Y. Makino, None.

To cite this abstract in AMA style:

Mizumoto K, Takatori K, Takatori S, Yoshimoto R, Eguchi K, Fujishiro D, Kodama S, Kobayashi A, Okamoto K, Kawaguchi Y, Haneda M, Makino Y. Pulmonary Arterial Hypertension-Associated Single Nucleotide Polymorphisms of Hypoxia-Inducible Factor-3a Gene Cause Constitutive Activation of the Endothelin-1 Gene Promoter [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/pulmonary-arterial-hypertension-associated-single-nucleotide-polymorphisms-of-hypoxia-inducible-factor-3a-gene-cause-constitutive-activation-of-the-endothelin-1-gene-promoter/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pulmonary-arterial-hypertension-associated-single-nucleotide-polymorphisms-of-hypoxia-inducible-factor-3a-gene-cause-constitutive-activation-of-the-endothelin-1-gene-promoter/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology